Key statistics
SmartText not available for this item.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.00 |
---|---|
High | 4.44 |
Low | 4.44 |
Bid | -- |
Offer | -- |
Previous close | 4.44 |
Average volume | -- |
---|---|
Shares outstanding | 1.55m |
Free float | 1.13m |
P/E (TTM) | -- |
Market cap | 1.82m USD |
EPS (TTM) | -19.73 USD |
Data delayed at least 15 minutes, as of Mar 13 2023 07:48 BST.
More ▼
Press releases
- Kiromic BioPharma Reports Favorable Ongoing Clinical Results From Fourth and Sixth Patients Enrolled in Deltacel-01
- Kiromic BioPharma Reports Favorable 10-Month Follow-Up Results for the First Patient Treated in its Deltacel-01 Clinical Trial
- Kiromic BioPharma Activates the University of Arizona Cancer Center as the Fifth Clinical Trial Site in the Ongoing Phase 1 Deltacel-01 Trial
- Kiromic BioPharma Advances Deltacel-01 Into Expansion Phase Following Safety Monitoring Committee’s Unanimous Recommendation
- Kiromic BioPharma’s Deltacel Receives FDA Fast Track Designation
- Kiromic BioPharma Provides Update on Part 1 of the Deltacel-01 Trial
- Kiromic BioPharma Reports 20% Tumor Size Reduction at Eight Months in First Patient Enrolled in Deltacel-01
- Kiromic BioPharma to Advance Deltacel-01 Clinical Trial to Part 2, Expansion Phase
More ▼